Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan-Dec:16:21501319251363156.
doi: 10.1177/21501319251363156. Epub 2025 Aug 16.

Diagnosis and Management of Alzheimer's Disease in Primary Care: A Real-World Study in Ontario, Canada

Affiliations

Diagnosis and Management of Alzheimer's Disease in Primary Care: A Real-World Study in Ontario, Canada

Zahinoor Ismail et al. J Prim Care Community Health. 2025 Jan-Dec.

Abstract

Objective: To understand the real-world clinical practice patterns and variation in Alzheimer's disease (AD) diagnostic and screening tool utilization by primary care physicians (PCPs), including tools used for assessing dementia/AD severity and subsequent treatment patterns.

Methods: This retrospective observational study used de-identified primary care data from electronic medical records (EMR) data provided by the researchers from Queen's University, Ontario, Canada from August 2011 to August 2021. Individuals ≥50 years old with dementia or AD were identified using AD and dementia-related diagnostic codes, medications, and keywords searched using natural language processing (NLP) and Artificial Intelligence (AI) algorithms from EMR chart notes. Diagnostic and screening tools included scales, neuroimaging, and laboratory tests. Medications examined were cholinesterase inhibitors, memantine, antidepressants, and antipsychotics.

Results: The study cohort included 417 individuals with all-cause dementia (mean [standard deviation: SD] age: 78.86 [0.19] years), and 71 individuals with AD (mean [SD] age: 76.13 [1.07]). The most-used scale was the Montreal Cognitive Assessment (MoCA; dementia: 53.2%, AD: 84.5%). The mean [SD] frequency of MoCA administration doubled in the year following AD index date compared to the year prior (0.29 [0.82] to 0.67 [1.19] times per patient-year). Severity scores, often unspecified, suggested various stages of cognitive impairment. Among the medications examined, cholinesterase inhibitors were prescribed in 27.8% (n = 116) and 57.8% (n = 41) of people with dementia and AD, respectively. Antidepressants were the most frequently prescribed medication examined (dementia: 49.6%; AD: 71.8%).

Conclusion: PCPs play an important role in the early detection and management of dementia/AD. As new biomarkers and therapies emerge for early AD, there is a need for connected health system data to guide PCPs through the early diagnostic process.

Keywords: Alzheimer’s disease; dementia; diagnosis; geriatrics; primary care.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ZI is funded by Alzheimer’s Drug Development Foundation, Brain Canada, CCNA, CIHR, NIA, and the Weston Foundation. He has been an investigator on clinical trials of monoclonal antibodies developed by Biogen and Roche and has served on Advisory Boards and Consultancies for Acadia, Biogen, Lundbeck/Otsuka, and Roche. MW, HK, and DBe are employed by Hoffmann-La Roche, who funded this study. MW and DBe hold Hoffmann-La Roche stock. ES, TP, and SM are employed by Medlior Health Outcomes Research Ltd., which received funding for the study from Hoffmann-La Roche. FZ, YC, NS, JC, and DBa are employed by Queen’s University, which also received funding for the study from Hoffmann-La Roche.

Figures

Covers study timeline for Alzheimer’s disease.
Figure 1.
Study schematic. Abbreviations: AD, Alzheimer’s disease.
The diagram is a flowchart illustrating the study cohort inclusion process for individuals diagnosed with dementia and Alzheimer’s disease. It begins with 831 individuals meeting the dementia algorithm and 830 with dementia identified via NLP chart note data. Exclusions are made for 413 individuals not fitting criteria, resulting in a dementia cohort of 422 and an Alzheimer’s disease cohort of 104. The flowchart details specific exclusion criteria for both cohorts and notes that they are not mutually exclusive. The Alzheimer’s disease cohort is part of the dementia cohort, and individuals within this subgroup have two index dates.
Figure 2.
Study cohort inclusion flowchart. Abbreviations: AD, Alzheimer’s disease; ICD-9-CM, the International Classification of Diseases, Ninth revision, Clinical Modification; NLP, natural language processing. aOne individual was excluded as they were misclassified by the dementia algorithm and did not meet the keyword inclusion criteria. bExclusion criteria are not mutually exclusive. cThe AD cohort is part of the dementia cohort. Individuals in the AD cohort have 2 index dates, 1 for meeting the dementia case definition and 1 for meeting the AD case definition.

Similar articles

References

    1. Alzheimer Society Canada. Navigating the path forward for dementia in Canada; Report 1. 2022 https://alzheimer.ca/sites/default/files/documents/Landmark-Study-Report...
    1. Manuel DG, Garner R, Finès P, et al. Alzheimer’s and other dementias in Canada, 2011 to 2031: a microsimulation Population Health Modeling (POHEM) study of projected prevalence, health burden, health services, and caregiving use. Popul Health Metr. 2016;14:37. - PMC - PubMed
    1. Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Neurology. 2023;100(4):180-192. doi: 10.1212/WNL.0000000000201541. - DOI - PubMed
    1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. doi: 10.15252/emmm.201606210. - DOI - PMC - PubMed
    1. De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016;164(4):603-615. doi: 10.1016/j.cell.2015.12.056. - DOI - PubMed

LinkOut - more resources